following a full submission
liraglutide (Victoza®) is accepted for use within NHS Scotland.
Indication under review: For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with basal insulin when this, together with diet and exercise, does not provide adequate glycaemic control.
The addition of liraglutide to basal insulin in combination with another anti-diabetic agent was associated with a significant reduction in HbA1c compared with placebo and an alternative insulin regimen.
Liraglutide has previously been accepted for restricted use as a third line antidiabetic agent for use in combination with oral antidiabetic agents. This now extends the advice to include its use in combination with insulin.
Download detailed advice192KB (PDF)
Medicine details
- Medicine name:
- liraglutide (Victoza)
- SMC ID:
- 1044/15
- Indication:
- For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with basal insulin when this, together with diet and exercise, does not provide adequate glycaemic control.
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 May 2015